Tracking a Cancer's identity shift: does losing a hormone target change the game?
NCT ID NCT07316439
Summary
This study looked at patients with advanced breast cancer to understand if losing the estrogen receptor (ER) target during the disease is different from having triple-negative breast cancer from the beginning. Researchers compared survival and treatment response between these two groups using advanced imaging and medical records. The goal was to gather knowledge to help guide future treatment decisions for patients whose cancer changes over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
Conditions
Explore the condition pages connected to this study.